niclosamide has been researched along with Cirrhosis in 4 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We explored the effects of niclosamide on TGF-β1-induced fibrosis in these cells and examined its underlying mechanism of action." | 8.31 | Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway. ( Guo, J; Li, W; Liu, X; Wang, J; Wu, X; Zhang, L, 2023) |
| " Importantly, niclosamide in vivo treatment of ALS-FUS mice reduces the expression of S100A4, α-SMA, and PDGFRβ in the spinal cord, as well as gliosis in central and peripheral nervous tissues, together with axonal impairment and displays beneficial effects on muscle atrophy, by promoting muscle regeneration and reducing fibrosis." | 8.02 | Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. ( Apolloni, S; Cozzolino, M; D'Ambrosi, N; Lattante, S; Mammarella, E; Miele, C; Milani, M; Rossi, S; Sabatelli, M, 2021) |
| "Niclosamide is a US Food and Drug Administration-approved oral antihelminthic drug used for treating most tapeworm infections." | 5.46 | The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression. ( Chang, X; Ding, K; Hu, Z; Liu, J; Nie, J; Ren, X; Zhen, X; Zhou, Z; Zhu, F, 2017) |
| " We explored the effects of niclosamide on TGF-β1-induced fibrosis in these cells and examined its underlying mechanism of action." | 4.31 | Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway. ( Guo, J; Li, W; Liu, X; Wang, J; Wu, X; Zhang, L, 2023) |
| " Importantly, niclosamide in vivo treatment of ALS-FUS mice reduces the expression of S100A4, α-SMA, and PDGFRβ in the spinal cord, as well as gliosis in central and peripheral nervous tissues, together with axonal impairment and displays beneficial effects on muscle atrophy, by promoting muscle regeneration and reducing fibrosis." | 4.02 | Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. ( Apolloni, S; Cozzolino, M; D'Ambrosi, N; Lattante, S; Mammarella, E; Miele, C; Milani, M; Rossi, S; Sabatelli, M, 2021) |
| "Niclosamide is a US Food and Drug Administration-approved oral antihelminthic drug used for treating most tapeworm infections." | 1.46 | The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression. ( Chang, X; Ding, K; Hu, Z; Liu, J; Nie, J; Ren, X; Zhen, X; Zhou, Z; Zhu, F, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Li, W | 1 |
| Liu, X | 1 |
| Guo, J | 1 |
| Wu, X | 1 |
| Wang, J | 1 |
| Milani, M | 1 |
| Mammarella, E | 1 |
| Rossi, S | 1 |
| Miele, C | 1 |
| Lattante, S | 1 |
| Sabatelli, M | 1 |
| Cozzolino, M | 1 |
| D'Ambrosi, N | 1 |
| Apolloni, S | 1 |
| Chang, X | 1 |
| Zhen, X | 1 |
| Liu, J | 1 |
| Ren, X | 1 |
| Hu, Z | 1 |
| Zhou, Z | 1 |
| Zhu, F | 1 |
| Ding, K | 1 |
| Nie, J | 1 |
| Morin, F | 1 |
| Kavian, N | 1 |
| Nicco, C | 1 |
| Cerles, O | 1 |
| Chéreau, C | 1 |
| Batteux, F | 1 |
4 other studies available for niclosamide and Cirrhosis
| Article | Year |
|---|---|
Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway.
Topics: Cell Proliferation; Cells, Cultured; Cicatrix; Fibroblasts; Fibrosis; Glaucoma; Humans; MAP Kinase S | 2023 |
Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Disease Models, Animal; Fibro | 2021 |
The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.
Topics: Animals; Anthelmintics; Carrier Proteins; Cells, Cultured; Disease Models, Animal; Doxorubicin; Fibr | 2017 |
Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.
Topics: Animals; Anthelmintics; Autoantibodies; B-Lymphocytes; Bleomycin; Cells, Cultured; Cytokines; Diseas | 2016 |